Insmed to Present at Biosimilars 2008 Conference
15 Septembre 2008 - 2:00PM
PR Newswire (US)
RICHMOND, Va., Sept. 15 /PRNewswire-FirstCall/ -- Insmed Inc.
(NASDAQ:INSM) a developer of follow-on biologics and
biopharmaceuticals, today announced that Geoffrey Allan, Ph.D., CEO
of Insmed, will present at the Biosimilars 2008 Conference in
Washington D.C. Dr. Allan will be discussing the Company's
perspective on the potential impact of follow-on biologics (FOB) on
American consumers and will also Chair a panel on this topic on
Tuesday, September 23, 2008 in the Jack Morton Auditorium at George
Washington University in Washington, D.C. Dr. Allan's presentation
will take place at 9:55 AM ET and the panel discussion will begin
at 11:25 AM ET. Biosimilars 2008 is a two day conference focusing
on the need for and applications of FOB, with an emphasis on issues
surrounding the possible establishment of a defined regulatory
pathway for FOB. About Insmed Insmed Inc. is a biopharmaceutical
company with unique protein process development and manufacturing
experience and a proprietary protein platform aimed at niche
markets with unmet medical needs. For more information, please
visit http://www.insmed.com/. Forward-Looking Statements This
release contains forward-looking statements which are made pursuant
to provisions of Section 21E of the Securities Exchange Act of
1934. Investors are cautioned that such statements in this release,
including statements relating to planned clinical study design,
regulatory and business strategies, strategic alternatives, plans
and objectives of management and growth opportunities for existing
or proposed products, constitute forward-looking statements which
involve risks and uncertainties that could cause actual results to
differ materially from those anticipated by the forward-looking
statements. The risks and uncertainties include, without
limitation, risks that strategic alternatives may never be
consummated, product candidates may fail in the clinic or may not
be successfully marketed or manufactured, we may lack financial
resources to complete development of product candidates, the FDA
may interpret the results of studies differently than us, competing
products may be more successful, demand for new pharmaceutical
products may decrease, the biopharmaceutical industry may
experience negative market trends, our entrance into the follow-on
biologics market may be unsuccessful, our common stock could be
delisted from The NASDAQ Capital Market and other risks and
challenges detailed in the Company's filings with the U.S.
Securities and Exchange Commission, including the Company's Annual
Report on Form 10-K for the year ended December 31, 2007. Readers
are cautioned not to place undue reliance on any forward-looking
statements which speak only as of the date of this release. The
Company undertakes no obligation to publicly release the results of
any revisions to these forward-looking statements that may be made
to reflect events or circumstances that occur after the date of
this release or to reflect the occurrence of unanticipated events.
Investor Relations Contact: Brian Ritchie - FD 212-850-5683
Corporate Communications Contact: John Procter - Gibraltar
Associates 202-879-5808 DATASOURCE: Insmed Inc. CONTACT: Investor
Relations Contact: Brian Ritchie of FD, +1-212-850-5683, ; or
Corporate Communications Contact: John Procter of Gibraltar
Associates, +1-202-879-5808, , both for Insmed Inc. Web site:
http://www.insmed.com/
Copyright
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024